70% Drop in Covid Vaccine Sales – $2.3B Losses – 1 Voice

or else $2.38 billion in losses. Despite the decline, however, the above performance was better than expected, as analysts expected a loss of 34 cents.

Revenue, meanwhile, shrank 42% from Q3 2022 to $13.23 billion, due to a big drop in Covid products.

Indicatively, vaccine sales shrank by 70% year-on-year, while sales of the drug Paxlovid plummeted by 97%.